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THE ROLE OF CORONARY 
REVASCULARIZATION IN 
RECIPIENTS OF AN 
IMPLANTABLE 
CARDIOVERTER- 
DEFIBRILLATOR 
The impact of adjuvant coronary revascularization was studied in a group 
of 138 recipients of an implantable cardioverter-defibriilator, all of whom 
had ischemic heart disease as the cause of their arrhythmias. Patients 
chosen for revascularization had more severe anatomic, symptomatic, or 
physiologic evidence of active ischemia. There were no operative deaths 
among 23 patients who actually underwent coronary artery bypass com- 
bined with cardioverter-defibrillator implantation; however, operative mor- 
tality by the intention-to-treat principle was 8% (2/25). Total cardiac 
survival was better for patients who underwent revascularization than for 
those patients who had "high-risk" characteristics and did not undergo 
revascularization. Stratified subgroup analysis demonstrated significant 
survival advantages favoring revascularization i  patients with three-vessel 
or left main coronary artery disease, class III or IV angina, and an ejection 
fraction greater than 25%. Multivariate analysis revealed that low ejection 
fraction and left main coronary artery disease were independent predictors 
of decreased survival. (J THORAC CARDIOVASC SURG 1995;110:1013-22) 
David M. Shahian, MD, Warren A. Williamson, MD, 
Ferdinand J. Venditti, Jr., MD, David T. Martin, MD, and 
Jonathan R. Ellis, MD, Burlington, Mass. 
S udden cardiac death (SCD) from ventricular tachycardia or fibrillation not associated with an 
acute myocardial infarction typically occurs in the 
presence of multivessel coronary disease (CAD) and 
myocardial scar. 1-3 Unless survivors of sudden car- 
diac death have previously undergone successful 
coronary artery bypass grafting (CABG) or percu- 
taneous transluminal coronary angioplasty, many 
will have persistent unrevascularized CAD with 
varying degrees of symptoms. When such patients 
are evaluated for implantation of a cardioverter- 
defibrillator (ICD), the possibility of concomitant 
coronary revascularization must be considered. The 
selection factors for adjuvant revascularization, the 
incremental impact on perioperative morbidity and 
mortality, and the effect of revascularization on 
long-term survival remain problematic. We investi- 
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gated these issues in a series of 138 patients with 
malignant arrhythmias who underwent ICD with or 
without concomitant coronary revascularization. 
Methods 
Study group. Of 171 ICD recipients, 138 had ischemic 
heart disease (CAD) as the major cause of arrhythmias. 
Several patients with minimal CAD had left ventricular 
dysfunction that was out of proportion to the extent of 
their CAD; they were thought o have idiopathic dilated 
cardiomyopathy as their primary cause of arrhythmias nd 
were not included in this study. 
Because of our interest in long-term follow-up, only 
those patients undergoing implantation of a complete 
ICD system were included in the study. Two patients 
underwent coronary revascularization and ICD patch 
implantation but died after the operation before under- 
going complete defibrillation threshold testing or ICD 
generator placement. These two patients were not in- 
cluded in the current study, but an intention-to-treat 
analysis of postoperative morbidity and mortality is pro- 
vided that includes them in the postoperative d ath data. 
Fifty-four group A patients had no unrevascularized 
CAD because of previous or concomitant coronary revas- 
cularization. Additional analysis was performed by subdi- 
viding these patients into group A1, 23 patients who 
underwent concomitant revascularization, and group A2, 
31 patients who had had previous revascularization. 
Group B included 84 patients who had unrevascularized 
CAD. For long-term survival analysis, group B was sub- 
divided into 63 group B1 patients (low-risk), who typically 
had one- or two-vessel disease and mild symptoms, and 21 
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group B2 patients (high-risk), who had indications for 
coronary artery bypass grafting (CABG) (class III or IV 
angina or three-vessel disease with impaired ventricular 
function or positive thallium study results) but could not 
be revascularized because of poor surgical targets, comor- 
bid disease, or other contraindications. 
Statistical methods. Postoperative mortality included all 
deaths occurring in the hospital. It also included those deaths 
occurring at home within 30 days after the operation, unless 
the cause of death was clearly unrelated to the operation. 
The latter category included only one patient who died at 
home on postoperative day 27 of a bradycardia, which in 
retrospect was believed by our electrophysiologist to have 
been present but unrecognized before the operation. Post- 
operative mortality has been calculated both with and with- 
out this patient included in the operative death data, and 
survival curves include him in the SCD data. 
Discrete variables were compared by means of the g a test 
or the Miettinen modification of Fisher's exact est. Contin- 
uous variables were compared by means of Student's t test or 
the Mann-Whitney test. Survival was analyzed by the 
Kaplan-Meier method with the differences between groups 
analyzed by Tarone-Ware testing , occasionally supple- 
mented by the Breslow or Mantel-Haenszel tests. Survival 
analysis included crude mortality (deaths from all causes), 
total cardiac mortality (including postoperative d aths and 
all late cardiac deaths), SCD flee survival (unwitnessed 
deaths or those occurring within 1 hour of onset of symp- 
toms), and non-SCD free survival. 
Surgical methods. All patients underwent preoperative 
electrophysiologic evaluation unless they had unstable an- 
gina or severe left main CAD. In such patients, CABG was 
performed, and patches and rate-sensing electrodes were 
placed at the time of the operation. Electrophysiologic 
testing was performed after recovery from the operation, 
and a generator was connected if appropriate. Three patients 
did not undergo any electrophysiologic testing. One had 
incessant spontaneous ventricular tachycardia that was pace 
terminable, one had severe left main CAD but could not 
undergo revascularization because of diffuse aortofemoral 
calcification, and one patient, after out-of-hospital cardiac 
arrest, was not studied because his arrhythmia had been 
noninducible on multiple previous attempts. 
The decision to revascularize was based on the patient's 
clinical degree of angina, angiographic extent of disease, 
objective vidence of ischemia, ejection fraction (EF) and 
its estimated impact on surgical mortality, other Comorbid 
conditions, and the presence of adequate surgical targets. 
All patients were monitored uring the operation with 
a Swan-Ganz catheter (Baxter Healthcare Corp., Edwards 
Div., Santa Ana, Calif.) and continuous mixed venous 
oxygen saturation, which determined the interval between 
arrhythmia inductions. Some patients underwent preop- 
erative intraaortic balloon pump support, particularly if
there was severe left ventricular dysfunction or extensive 
CAD that could not be revascularized. 
Defibrillation threshold testing was carried out beginning 
at 15 joules and proceeding ina stepwise fashion. A 10-joule 
buffer between the measured defibrillation threshold and the 
output of the generator was considered adequate. 
A one-stage combined procedure was performed when- 
ever possible. If the patient was in stable condition in the 
operating room after revascularization, limited electro- 
physiologic testing was performed without cardiopulmo- 
nary bypass or with low-flow bypass and a full heart. A 
study by Blakeman and associates 4 demonstrated that 
despite the residual effects of cardioplegia, cooling, and 
operative ischemia, the testing results obtained immedi- 
ately after the termination of cardiopulmonary b pass 
were comparable with those obtained at subsequent test- 
ing. In patients who are in unstable condition at the end of 
cardiopulmonary b pass, it is prudent o bury the leads in 
an abdominal pocket and conduct definitive testing and 
generator implantation after 1 week. 
Results 
Preoperative demographics and descriptive statistics 
are given in Table I. There were no statistically signif- 
icant differences except for a higher incidence of 
three-vessel or left main CAD, class III or IV angina, 
and previous cardiac operation in group A patients. 
Further stratification (Table II) reveals that the class 
II I  or IV symptoms or positive stress test results 
occurred almost exclusively in patients who were to 
undergo concomitant CABG (group A1). Patients 
who had had previous revascularization (group A2) 
had a minimal ischemic burden according to symp- 
toms and stress testing. Overall, 12 of 30 patients 
(40%) with positive results of stress testing underwent 
concomitant coronary revascularization as opposed to 
only 4 of 35 patients (11.4%) who had negative stress 
test results (p = 0.0097). Similarly, 11 of 16 patients in 
the overall series (68.8%) who had class II I  or IV 
angina underwent concomitant coronary revascular- 
ization as opposed to only 8 of 112 patients (7.1%) 
who had class I or II angina (p = 0.0001). 
Preoperative intraaortic balloon pumping was used 
in 25 patients (29.8%) in group B, a significantly higher 
percentage than in group A (six patients, 11.1%, p = 
0.0098). Balloon pumps were used more frequently in 
group B because these patients had unrevascularized 
CAD, and it was hoped that the balloon pump would 
protect against intraoperative ischemia. Of 23 group A 
patients undergoing concomitant coronary operations, 
10 patients (43.5%) underwent a staged procedure 
with delayed generator implantation and 13 patients 
(56.5%) underwent one-stage implantation of the en- 
tire system. 
Formal defibrillation thresholds were available 
for 127 patients, being lower for group B than for 
group A patients (13.4 _ 5.1 joules versus 16.6 ___ 4.9 
joules, p = 0.0005). There was no significant differ- 
ence in lead impedance in the 82 patients in whom 
this variable was recorded (group A = 39.9 _+ 8.7 
ohms; group B = 43.6 _ 8.5 ohms; p = 0.0553). 
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Table I. Preoperative data 
Group A Group B p 
(n = 54) (n = 84) Value 
Sex: No. (%) 
Male 45 (83.3) 71 (84.5) 1.000 
Female 9 (16.7) 13 (15.5) 
Age (yr): median (range) 67.0 (41-83) 67.5 (33-80) 0.5323 
Arrhythmia history: No. (%) 
Syncope 14 (25.9) 26 (31.0) 
Cardiac arrest 25 (46.3) 32 (38.1) 0.6271 
Monomorphic VT 15 (27.8) 26 (31.0) 
Prior MI: No. (%) 52 (96.3) 80 (95.2) 1.000 
Extent of CAD: No. (%) 
One vessel 6 (11.1) 29 (34.5) 
Two vessel 7 (13.0) 28 (33.3) 
Three vessel 37 (68.5) 24 (28.6) * 
Left main 4 (7.4) 3 (3.6) 
Prior CV operation 33 (61.1) 20 (23.8) <0.0001 
EF (%) 31.1 - 9.8 29.4 _+ 12.3 0.3801 
LVA: No. (%) 8 (14.8) 21 (25.0) 0.1578 
Stress test: No. (%)t 
Negative 15 (53.6) 20 (54.1) 
Positive 13 (46.4) 17 (46.0) 0.9695 
Angina: No. (%) (data avail- 
able for 128 cases) 
Class I 31 (63.3) 56 (70.9) 
Class II 7 (14.3) 18 (22.8) 
Class III 8 (16.3) 5 (6.3) :~ 
Class IV 3 (6.1) 0 (0.0) 
VZ, Ventricular tachycardia; MI, myocardial infarction; CAD, coronary artery disease; CV, cardiovascular; EF, ejection fraction; LVA, left ventricular neurysm. 
*Forty-one of 54 (75.9%) group A patients had three-vessel or left main CAD compared with 27 of 84 (32.1%) group B patients (p < 0.0001). 
tData are available for 65 patients. 
:~Data re available for 128 patients. Of those, 11 of 49 (22.4%) group A patients had class III or IV angina compared with 5 of 79 patients (6.3%) in group 
B (p = 0.0105). 
Table II. Preoperative characteristics of group A patients who underwent concomitant CABG (group A1) 
versus those previously revascularized (group A2) 
Group A1 Group A2 p 
(n = 23) (n = 31) Value 
Angina: No. (%) 
Unknown 4 (17.4) 1 (3.2) 
Class [ 4 (17.4) 27 (87.1) 
Class II 4 (17.4) 3 (9.7) 0.00001 
Class III 8 (34.8) 0 
Class IV 3 (13.0) 0 
Stress test: No. (%) 
Not done 7 (30.4) 19 (61.3) 
Negative 4 (17.4) 11 (35.5) 0.00017 
Positive 12 (52.2) 1 (3.2) 
CAD extent: No. (%) 
One vessel 1 (4.3) 5 (16.1) 
Two vessel 2 (8.7) 5 (16.1) 
Three vessel 17 (73.9) 20 (64.5) 0.2508 
Left main 3 (13.0) 1 (3.2) 
Operative morbidity and mortality analysis (Table 
III) revealed a higher requirement for use of ino- 
tropic drugs in patients undergoing concomitant 
revascularization (p < .0001), probably because of 
prolonged cardiopulmonary bypass and postbypass 
defibrillation threshold testing, and a higher but not 
statistically significant incidence of atrial and ven- 
tricular arrhythmias in this group. Postoperative 
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Table I I I .  Perioperative morbidity and mortafity 
Group A1 Group A2 Group B p 
(n = 23) (n = 31) (n = 84) Value 
Death: No. (%) 0 
MI: No. (%) 0 
VT/VF: No. (%) 5 (21.7) 
AF: No. (%) 9 (39.1) 
CHF: No. (%) 0 
Heart block: No. (%) 0 
Tamponade: No. (%) 0 
Inotropic drugs/IABP: No. (%) 17 (73.9) 
ARDS: No. (%) 0 
Pneumonia/bronchitis: No. (%) 2 (8.7) 
Atelectasis/lobar collapse: No. (%) 1 (4.4) 
Prolonged intubation: No. (%) 2 (8.7) 
Pulmonary embolism: No. (%) 0 
Revision: No. (%) 0 
Hemothorax (drainage): No. (%) 7 (30.4) 
Hemothorax (reoperation): No. (%) 1 (4.4) 
Pneumothorax: No. (%) 2 (8.7) 
Prolonged air leak: No. (%) 0 
Retroperitoneal hematoma: No. (%) 1 (4.4) 
Wound seroma, erythema, hema- 0 
toma (no treatment): No. (%) 
Generator hematoma drain: No. (%) 2 (8.7) 
Generator erosion: No. (%) 0 
IABP complication: No. (%) 0 
Neurologic: No. (%) 3 (13.0) 
Urinary tract infection: No. (%) 2 (8.7) 
Urinary retention: No. (%) 1 (4.4) 
Upper GI tract bleeding: No. (%) 0 
ATN: No. (%) 0 
Ileus: No. (%) 1 (4.4) 
0 2 (2.4) 0.5208* 
2 (6.5) 8 (9.5) 0.2902 
2 (6.5) 12 (14.3) 0.2661 
4 (12.9) 18 (21.4) 0.0690 
1 (3.2) 10 (11.9) 0.0946 
0 1 (1.2) 0.7234 
0 1 (1.2) 0.7234 
1 (3.2) 5 (6.0) t 
0 1 (1.2) 0.7234 
1 (3.2) 3 (3.6) 0.5323 
2 (6.5) 12 (14.3) 0.2663 
1 (3.2) 5 (6.0) 0.6932 
0 1 (1.2) 0.7234 
1 (3.2) 0 0.1758 
0 1 (1.2) 0.0000 
0 0 0.0806 
1 (3.2) 1 (1.2) 0.1629 
1 (3.2) 1 (1.2) 0.5878 
0 2 (2.4) 0.5442 
0 4 (4.8) 0.1941 
0 0 0.0063 
0 1 (1.2) 0.7234 
1 (3.2) 1 (1.2) 0.5878 
0 1 (1.2) 0.0061 
0 4 (4.8) 0.2881 
1 (3.2) 2 (2.4) 0.8766 
0 1 (1.2) 0.7234 
0 2 (2.4) 0.5208 
1 (3.2) 1 (1.2) 0.5903 
MI, Myocardial infarction; VT/VF, ventricular tachycardia/ventricular fibrillation; AF, atrial fibrillation; CHF, congestive heart failure; IABP, intraaortic 
balloon pump; ARDS, adult respiratory distress yndrome; ATN, acute tubular necrosis. 
*If the two patients are included who underwent CABG but died before ICD testing and implantation, the respective mortality rates are as follows: group 
A1 = 2/25 (8%), group A2 = 0/31, group B = 2/84 (2.4%),p = 0.1861. If the one group B patient is included who died at home of apparently preexisting 
disease on postoperative day 27, the mortality rates would be as follows: group A1 = 0/23, group A2 = 0/31, group B = 3/84 (3.6%),p = 0.3732. If all three 
of these patients are included, the rates would be as follows: group A1 = 2/25 (8%), group A1 = 0/31, group B = 3/84 (3.6%), p = 0.2764. 
tGroup A1 versus A2, p < 0.000l; group A1 versus B, p < 0.0001; group A2 versus B, p = 0.6291. 
pleural effusions necessitating therapy and genera- 
tor hematomas necessitating drainage were also 
more prevalent, the latter occurring exclusively in 
patients receiving postoperative anticoagulation. 
Three patients (13%) had neurologic complications 
after concomitant CABG and ICD--generalized 
encephalopathy in one instance, a transient ischemic 
attack in another, and a cerebrovascular accident in 
a third. This incidence of complications was higher 
than in the other two groups (p = 0.0061). 
Median postoperative hospital stays were 9 days in 
group A and 8 days in group B (p = 0.6265). Approx- 
imately one quarter of the patients in each group were 
discharged receiving antiarrhythmic medications. 
Mean patient follow-ups for groups A and B were, 
respectively, 27.9 months (range 0.7 to 59.8 months) 
and 24.0 months (range 0.1 to 59.5 months). 
Crude, total cardiac, non-SCD free, and SCD free 
survival for groups A and B are depicted in Fig. 1. 
These demonstrate highly significant survival advan- 
tages for patients who had no unrevascularized 
CAD (group A) compared with the 21 patients with 
"high-risk" unrevascularized CAD (group B2) who 
could not undergo revascularization because of 
technical factors or comorbid disease. This advan- 
tage was noted in crude (p = 0.0215), total cardiac 
(p = 0.0086), and SCD free survival (p = 0.0131) 
determinations. Subgroup analysis revealed that sur- 
vival was enhanced by revascularization in patients 
with class III or IV angina (p = 0.0268), three-vessel 
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Fig. 1. A, Crude survival (all causes of death) for patients without (group A, n = 54) unrevascularized 
CAD, patients with <<low-risk" unrevascularized CAD (group B1 = 63 patients), and patients with 
"high-risk" unrevascularized CAD (group B2 = 21 patients). Bars indicate standard error. Group A 
patients had the best survival, significantly (p = 0.0215) better than that of the high-risk unrevascularized 
patients (group B2). B, Total cardiac survival (includes SCD, non-SCD, and postoperative cardiac deaths) 
for groups A, B1, and B2. Group A patients had significantly better survival than the high-risk unrevascularized 
patients in group B2 (p = 0.0086). C, Non-SCD free survival for groups A, B1, and B2. No statistically significant 
differences were found. D, SCD free survival for groups A, B1, and B2. Group A patients had significantly (p= 
0.0131) better survival than the high-risk unrevascularized patients (group B2). 
or left main CAD (p = 0.0395), or EF greater than 
25% (p = 0.0282) (Figs. 2 to 4). 
Univariate survival analysis was performed for 
the entire series of 138 patients with malignant 
arrhythmias and CAD. Significant univariate pre- 
dictors of diminished survival included left main 
CAD (/9 < 0.001) and use of preoperative in- 
traaortic balloon pumping (p = 0.0120 for total 
cardiac mortality). The latter was used in patients 
believed to be at high risk for perioperative 
ischemia who could not undergo revasculariza- 
tion. These patients would still be at higher risk of 
recurrent ischemia during long-term follow-up, 
which accounts for their decreased survival in 
univariate analysis (but not in multivariate analy- 
sis, in which confounding variables are con- 
trolled). Multivariate analysis was performed by 
means of the Cox proportional hazards model 
with all cardiac deaths as the end point. Variables 
analyzed included age, sex, history, clinical pre- 
sentation, EF, CAD extent (left main versus oth- 
er), angina (classes I/II versus III/IV), thallium 
(positive/negative), unrevascularized CAD, con- 
comitant operation, prior cardiac operation, and 
preoperative intraaortic balloon pumping. When 
EF was analyzed as a dichotomous variable 
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Fig. 2. A, Total cardiac survival for patients with EF of 25% or less, stratified by presence or absence of 
unrevascularized CAD. There is no difference in survival, which is limited primarily by poor ventricular 
function. B, Total cardiac survival for patients with EF greater than 25%, stratified by presence or absence 
of unrevascularized CAD. There is a significant positive effect of revascularization in these patients with 
better ventricular function. 
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Fig. 3. A, Total cardiac survival for patients with one- or two-vessel CAD, stratified by presence or absence 
of unrevascularized CAD. There is no statistically significant difference, although survival was 100% for 
those patients who underwent revascularization. B, Total cardiac survival for patients with three-vessel or 
left main CAD, stratified by presence or absence of unrevascularized CAD. There is a statistically 
significant improvement in survival in patients undergoing revascularization. 
(-<25%, >25%) ,  it violated the proport ional  haz- 
ards assumptions. Therefore  EF  was analyzed as a 
cont inuous variable. Stepwise forward regression 
selected low EF  (coefficient = -0 .0633;  standard 
error  = 0.0271; p = 0.0118) and left main CAD 
(coefficient = 1.8761; standard error  = 0.5303; 
relative risk = 6.53, [2.3 to 18.5]; p = 0.0056) as 
predictive variables for total cardiac mortal ity. 
The effect of  EF  on survival with CAD,  with or 
without SCD, is well known. Patients in our  study 
with left main CAD were a uniquely high-risk 
group. The mean EF  of  these seven patients was 
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Fig. 4. A, Total cardiac survival for patients with New York Heart Association class I or II angina, 
stratified by presence or absence of unrevascularized CAD. Revascularization has no impact on survival. 
B, Total cardiac survival for patients with class III or IV angina, stratified by presence or absence of 
unrevascularized CAD. There is a highly significant difference favoring revascularization in these patients. 
only 23.6% (range 15% to 35%). Four of the seven 
patients did not undergo concurrent revascularization 
because of profound left ventricular dysfunction (EF 
18%) combined with absent symptoms and negative 
results of a thallium study in one patient, a diffusely 
calcified aorta in one patient, an EF of 15% in a third 
patient, and prior successful revascularization i  a 
fourth patient. The combination ofleft main CAD and 
malignant arrhythmias i particularly ominous, espe- 
daily if revascularization cannot be performed. 
Discussion 
SCD affects 300,000 to 400,000 individuals per 
year in the United States, with a 2-year recurrence 
rate of 40%. 3 Although significant multivessel CAD 
and a history of a remote myocardial infarction are 
present in most, only 15% to 30% of such patients 
had evidence of an acute myocardial infarction at 
the time of their SCD episode. 1-3' s 
The most common cause of SCD in patients with 
atherosclerotic CAD is scar resulting from a previ- 
ous infarction. This scar leads to abnormal and 
heterogeneous conduction and refractoriness, en- 
hanced automaticity, and a fragmented electro- 
gram, 3which is the anatomic and electrophysiologic 
substrate of sustained monomorphic ventricular 
tachycardia. This reentrant circuit does not require 
an ischemic trigger, although ischemia may be 
present in some cases. Prearrest angina is not a 
common finding in SCD unassociated with myocar- 
dial infarction, and in pathologic studies of patients 
having SCD, acute coronary lesions are often ab- 
sent.i, 6 Fortuitous Holter monitor recordings im- 
mediately preceding an episode of SCD have in- 
frequently revealed premonitory ischemic S-T 
changes. 3 Meissner, Akhtar, and Lehmann I esti- 
mated that nonischemic sustained monomorphic 
ventricular tachycardia accounts for 20% to 40% of 
sudden tachyarrhythmic cardiac deaths unrelated to 
acute infarction and that these ventricular tachycar- 
dias often degenerate into ventricular fibrillation. 
Despite the predominance of myocardial scar as 
an anatomic and physiologic substrate, ischemia 
may be a cofactor in some cases of SCD. For 
example, the circadian variability of SCD correlates 
with the increased morning incidence of acute isch- 
emic cardiac events. 2'3'7 Meissner, Akhtar, and 
Lehmann 1 estimated that one to two thirds of SCD 
survivors have both an arrhythmogenic s ar and 
ischemia. Pure ischemic SCD occurs in only 10% to 
15% of patients with CAD and is associated with a 
higher incidence of angina, noninducibility, absence 
of a myocardial scar, and favorable response to 
revascularization. 1 
Some inferences regarding the association among 
ischemia, revascularization, and SCD can be made 
from several prospective randomized trials con- 
ducted in the United States and Europe. Holmes 
and associates a reported on the prevalence of SCD 
in the Coronary Artery Surgery Study (CASS) reg- 
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istry. SCD occurred in 5.2% of 6260 medically 
treated patients compared with 1.8% of 7216 surgi- 
cally treated patients. The difference was statistically 
significant for patients with two- and three-vessel 
disease and no congestive heart failure, but was 
particularly striking in patients with two-vessel dis- 
ease and congestive heart failure (98% surgical 
versus 83% medical, p < 0.001) and three-vessel 
disease with congestive heart failure (91% surgical 
versus 69% medical, p < 0.001). Ten-year follow-up 
of the randomized 780 patients in the Coronary 
Artery Surgery Study revealed a higher percentage 
of myocardial infarction and SCD in medically 
treated patients, but the difference did not reach 
statistical significance. 9 In the European Prospective 
Randomized Coronary Surgery Study, 1° which ex- 
cluded patients with poor left ventricular function, 
the cumulative risk of SCD at 8 years was 3% in the 
surgically treated group and 9% in the medically 
treated group (p = 0.00046). 
Several nonrandomized studies also have noted 
the impact of coronary revascularization survival 
after SCD. Wilber and associates 5 performed a 
multivariate analysis of risk factors for recurrent 
cardiac arrest in 166 survivors of SCD not associated 
with myocardial infarction. Absence of coronary 
revascularization carried a relative risk of 4.2 (p = 
0.05). Every and associates 11reported on 265 pa- 
tients resuscitated from SCD caused by ventricular 
fibrillation, 32% of whom underwent CABG and 
68% of whom were treated medically. Preopera- 
tively, the surgically treated group had a 58% inci- 
dence of angina compared with 35% in the medi- 
cally treated group (p < 0.01), a higher EF (51.7% 
versus 41.2%, p < 0.001), and a lower incidence af 
acute myocardial infarction (17% versus 32%, p < 
0.001). CABG reduced the risk of recurrent SCD 
(risk ratio 0.48,p < 0.04) and total cardiac mortality 
(risk ratio 0.65,p = 0.10). Bolooki and associates lz 
found that concomitant revascularization increased 
the shock-free survival of ICD recipients during a 
6-year follow-up compared with patients who did 
not undergo revascularization (41% versus 21%). 
The rate of subsequent SCD was lower (2.39% per 
patient-year versus 3.5% per patient-year). 
Physiologic tests for myocardial ischemia provide 
additional information supporting some relationship 
between ischemia and SCD. In a report from the 
Coronary Artery Surgery Study, Weiner and col- 
leagues 13 studied the incidence of myocardial infarc- 
tion and SCD over 7 years, comparing patients with 
silent as opposed to symptomatic schemia during 
exercise testing. Compared with results in control 
patients, who had a 98% 7-year survival free of 
myocardial infarction and SCD, the 74% 7-year 
survival of patients with asymptomatic ischemic 
changes and 77% survival of patients with symptom- 
atic ischemic hanges on exercise testing were sub- 
stantially lower (p < 0.001). However, it is not 
entirely clear what proportion of SCDs had an 
arrhythmic origin. In the subset of patients with 
three-vessel coronary disease, patients with symp- 
tomatic ischemia had a 93% 7-year SCD free sur- 
vival as compared with 79% in the asymptomatic 
group (p = 0.001). Despite these data, it must be 
acknowledged that when SCD survivors are moni- 
tored during exercise, most studies have demon- 
strated a low incidence of exercise-induced ischemia 
and arrhythmias. ~4-16 
Finally, several investigators have focused on 
patients with malignant rhythms other than sus- 
tained monomorphic VT that are more likely of a 
purely ischemic origin. These data suggest hat 
primary ventricular fibrillation 17 and polymorphic 
ventricular tachycardia j8 are more often ischemic 
in origin and may respond to revascularization, 
but the risk of recurrent arrhythmias i not always 
eliminated. 19 
With the advent of ICD therapy and subendocar- 
dial resection, the available treatment modalities to 
prevent recurrent SCD have expanded ramatically. 
In experienced centers, patients with mappable ar- 
rhythmias, left ventricular aneurysms, and good 
function of the residual myocardium ay undergo 
subendocardial resection, with or without bypass or 
ICD, with a mortality under 10%. 2°' 21 However, 
many patients do not meet he criteria for "curative" 
therapy and are treated with an ICD. Given the 
inconclusive data presented on the role of ischemia 
in SCD, the indications for revascularization i
these patients are unclear. 
Some evidence suggests that revascularization 
may have a salutary effect in selected ICD recipi- 
ents. Levine and associates 22studied 197 patients 
who survived ICD implantation with or without 
CABG. Cox multivariate analysis revealed that re- 
vascularization was associated with later ICD dis- 
charge and improved survival after ICD discharge. 
Wilber and associates 23studied 64 patients receiving 
ICDs. Of 49 patients with CAD, 28 underwent ICD 
implantation plus concomitant coronary revascular- 
ization. Lack of concomitant coronary revasculariza- 
tion was a univariate and multivariate (relative risk, 
2.9) predictor of early ICD discharges. 
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Despite the evidence supporting a salutary effect 
of revascularization, a decision to add concomitant 
CABG may significantly increase the immediate 
perioperative risk. This increased risk may result 
from the longer operative time, extensive defibrilla- 
tion testing at the end of cardiopulmonary b pass 
when the heart has already sustained ischemic in- 
jury, or from the potential pulmonary and cardiac 
effects of amiodarone hydrochloride (Cordarone, 
Wyeth-Ayerst Laboratories, Philadelphia, Pa.). 24 In 
the series of Elefteriades and associatesY operative 
mortality for !CD alone was 3.3% and for ICD plus 
CABG, 10.7%. Pinski and associates 26reported a 
postoperative mortality rate of 11.8% for combined 
CABG plus ICD and 8.9% if the two procedures 
were staged. Gohn and associates 27reported a mor- 
tality rate for isolated ICD placement of 3.3% in 183 
patients and 6.8% in 88 patients who underwent 
concomitant heart operations (p = 0.15). In recent 
work from the planning phase of the CABG Patch 
Trial, Bigger 2s reported more favorable results in a 
series of 125 patients. Operative mortality was 4.8% 
for CABG plus ICD. Bolooki and associates 12re- 
ported an operative mortality of 2% among 43 
patients undergoing ICD and CABG and 2.9% 
among ICD recipients without CABG. 
Infection is also more common after combined 
ICD-CABG, whether an entire ICD system or only 
patches are placed, 29 and may be the result of patch 
implantation i a surgical wound that has been open 
for many hours. Infection also may result from 
postbypass immunologic depression. 24
In our series, ICD recipients were chosen for 
revascularization primarily on the basis of the an- 
giographic extent of CAD, objective and subjec- 
tive evidence of ischemia, and availability of 
surgical targets. Revascularization combined with 
ICD placement was accomplished with low mortality 
and morbidity, with the exception of a higher inci- 
dence of inotropic use and neurologic events. Long- 
term survival was better in patients undergoing 
revascularization than in the "high-risk" group B2 
patients. 
These findings uggest that revascularization may 
be a valuable adjunct in the treatment of malignant 
arrhythmias in patients with CAD. Revasculariza- 
tion may decrease the nonarrhythmic complications 
of CAD and may favorably influence the incidence 
of those arrhythmias that have either a purely 
ischemic basis or a combination of an ischemic and 
a reentrant mechanism. 
Our study does not address the question of how to 
treat patients who have primarily ischemic symp- 
toms but who are thought o be at high risk for the 
development of malignant arrhythmias. 3° This sub- 
ject is being investigated in the CABG Patch Trial. 28 
We thank Gerald Heatley, MA, for his help with 
statistical analysis. 
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